Amexdrug Corporation
AXRX
$0.002
$0.000.00%
| 06/30/2013 | 03/31/2013 | 12/31/2012 | 09/30/2012 | 06/30/2012 | |
|---|---|---|---|---|---|
| Revenue | -12.19% | -20.59% | -26.26% | -23.48% | -14.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.19% | -20.59% | -26.26% | -23.48% | -14.85% |
| Cost of Revenue | -17.48% | -24.52% | -28.61% | -21.64% | -13.31% |
| Gross Profit | 46.71% | 25.41% | 0.63% | -39.57% | -28.96% |
| SG&A Expenses | 8.95% | 4.35% | 2.46% | 4.58% | 10.22% |
| Depreciation & Amortization | 437.63% | 335.00% | 201.54% | 102.00% | 82.35% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.02% | -22.27% | -26.53% | -19.90% | -11.80% |
| Operating Income | 682.51% | 156.22% | -11.56% | -107.77% | -91.03% |
| Income Before Tax | 1,698.74% | 206.52% | -14.61% | -113.69% | -96.40% |
| Income Tax Expenses | 2,571.11% | 139.80% | -10.19% | -117.42% | -97.28% |
| Earnings from Continuing Operations | 1,355.26% | 270.20% | -18.39% | -111.58% | -95.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,355.26% | 270.20% | -18.39% | -111.58% | -95.87% |
| EBIT | 682.51% | 156.22% | -11.56% | -107.77% | -91.03% |
| EBITDA | 639.42% | 168.29% | -5.49% | -105.75% | -89.20% |
| EPS Basic | -- | 300.00% | -33.33% | -116.67% | -100.00% |
| Normalized Basic EPS | 900.00% | 200.00% | -14.29% | -111.76% | -93.33% |
| EPS Diluted | -- | 300.00% | -33.33% | -116.67% | -100.00% |
| Normalized Diluted EPS | 900.00% | 200.00% | -14.29% | -111.76% | -93.33% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
